Rodman & Renshaw initiated coverage of Coya Therapeutics with a Buy rating and $18 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya publishes ALS study in peer-reviewed Frontiers in Neurology
- Coya completes of Phase 2 study of LD IL-2 to treat moderate AD
- Coya Therapeutics announces $5M strategic investment from ADDF
- Coya Therapeutics Financial and Operational Results Overview
- Coya Therapeutics reports Q1 EPS (35c) vs (28c) last year